This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Gong, X.
Right arrow Articles by Tien, P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gong, X.
Right arrow Articles by Tien, P.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, November 2009, p. 1595-1600, Vol. 16, No. 11
1071-412X/09/$08.00+0     doi:10.1128/CVI.00160-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Glycoprotein 96-Mediated Presentation of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific Human Leukocyte Antigen Class I-Restricted Peptide and Humoral Immune Responses to HIV-1 p24{triangledown}

XiaoYan Gong,1 WeiWei Gai,1 JunQiang Xu,1 Wei Zhou,1 and Po Tien1,2*

Modern Virology Research Center, State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, China,1 Center for Molecular Virology, CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China2

Received 11 April 2009/ Returned for modification 6 May 2009/ Accepted 15 September 2009

Viral antigens complexed to heat shock proteins (HSPs) can enhance antiviral immunity. The present study evaluated the immunogenicity of a novel human immunodeficiency virus type 1B' (HIV-1B')-specific, human leukocyte antigen A2 (HLA-A2)-restricted peptide (FLQSRPEPTA, Gag448-457) and the cellular immune adjuvant effect of HSP gp96 using the HLA-A2 transgenic mouse model. It was found that gp96 could augment cytotoxic-T-lymphocyte responses specific for the 10-mer peptide of HIV-1B'. This study also evaluated the humoral immune adjuvant effect of HSP gp96 and its N-terminal fragment (N336) and found that immunization of BALB/c mice with a mixture of gp96 or its N-terminal fragment and HIV-1 p24 antigen or with an p24-N336 fusion protein resulted in a significant increase in anti-HIV p24 antibody titer. These results demonstrate the possibility of using gp96 and its N fragment as adjuvants to augment cellular and humoral immune responses against HIV-1 infection.

* Corresponding author. Mailing address: Center for Molecular Virology, CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China. Phone: 86-10-64807520. Fax: 86-10-64807381. E-mail: tienpo{at}sun.im.ac.cn

{triangledown} Published ahead of print on 23 September 2009.

Clinical and Vaccine Immunology, November 2009, p. 1595-1600, Vol. 16, No. 11
1071-412X/09/$08.00+0     doi:10.1128/CVI.00160-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»